Literature DB >> 3050910

Significance of duct-acinar dysplasia in prostatic carcinogenesis.

J E McNeal1.   

Abstract

Duct-acinar dysplasia of the prostate is defined as a premalignant lesion characterized by cytologic, and especially nuclear, abnormalities that resemble those of carcinoma and affect the lining epithelial cells of preexisting ducts and acini. A progressive continuum of cytologic abnormality is divided into three grades, with grade III identified by the presence of numerous large nucleoli. Foci of carcinoma have been identified at their point of origin from dysplastic ducts, which confirms the malignant potential of this lesion. Foci of dysplasia are found in roughly 80% of prostates with invasive carcinoma and 40% of glands without cancer. It is concluded that the majority of prostate cancers probably arise within dysplasia foci. Foci of grade III dysplasia occasionally evolve by proliferation of cells to fill duct lumens. The intraluminal cell masses display a cribriform pattern, which has previously been interpreted as a variant of invasive Gleason grade 3 carcinoma. Dysplasia is further linked biologically to malignant transformation by the immunohistochemical demonstration of progressive loss of cytoplasmic differentiation markers and inappropriate overexpression of some markers during the evolution of dysplasia.

Entities:  

Mesh:

Year:  1988        PMID: 3050910     DOI: 10.1002/pros.2990130202

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  2 in total

Review 1.  Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance.

Authors:  R Montironi; R Mazzucchelli; F Algaba; A Lopez-Beltran
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

Review 2.  Current Understanding and Management of Intraductal Carcinoma of the Prostate.

Authors:  Bryden Considine; Adebowale Adeniran; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.